Jan Nils Sandström

Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved.

NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden.

TikoMed AB is a Swedish pharmaceutical company that develops pharmaceutical products. The private company is based in Viken, Sweden. The company was founded by Adam Bruce, Lars Bruce. Anders Kristensson has been the CEO of the company since 2018.

Sveriges Aktiesparares Riksförbund is an organization working in the interests of private individuals who invest in stocks, mutual funds, and other stock related securities. It offers information and education, stock trading services, and small shareholder rights plan. The company was founded on February 5, 1966 and is headquartered in Stockholm, Sweden.

Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden.